223 related articles for article (PubMed ID: 35397526)
1. Liraglutide preserves CD34
Sforza A; Vigorelli V; Rurali E; Perrucci GL; Gambini E; Arici M; Metallo A; Rinaldi R; Fiorina P; Barbuti A; Raucci A; Sacco E; Rocchetti M; Pompilio G; Genovese S; Vinci MC
Cardiovasc Diabetol; 2022 Apr; 21(1):51. PubMed ID: 35397526
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
Shi L; Ji Y; Jiang X; Zhou L; Xu Y; Li Y; Jiang W; Meng P; Liu X
Cardiovasc Diabetol; 2015 Feb; 14():18. PubMed ID: 25855361
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
4. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.
Barale C; Buracco S; Cavalot F; Frascaroli C; Guerrasio A; Russo I
Thromb Haemost; 2017 Jun; 117(6):1115-1128. PubMed ID: 28405672
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
10. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.
Janez A; Muzurovic E; Stoian AP; Haluzik M; Guja C; Czupryniak L; Duvnjak L; Lalic N; Tankova T; Bogdanski P; Papanas N; Nunes JS; Kempler P; Fras Z; Rizzo M
Int J Cardiol; 2022 Oct; 365():8-18. PubMed ID: 35905827
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
McLean BA; Wong CK; Kabir MG; Drucker DJ
Mol Metab; 2022 Dec; 66():101641. PubMed ID: 36396031
[TBL] [Abstract][Full Text] [Related]
13. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
Shu X; Zhang Y; Li M; Huang X; Yang Y; Zeng J; Zhao Y; Wang X; Zhang W; Ying Y
Neuropharmacology; 2019 Jul; 153():1-12. PubMed ID: 31015047
[TBL] [Abstract][Full Text] [Related]
14. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
Kumari P; Nakata M; Zhang BY; Otgon-Uul Z; Yada T
Biochem Biophys Res Commun; 2018 May; 499(3):618-625. PubMed ID: 29601817
[TBL] [Abstract][Full Text] [Related]
16. Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.
Ghosh P; Fontanella RA; Scisciola L; Pesapane A; Taktaz F; Franzese M; Puocci A; Ceriello A; Prattichizzo F; Rizzo MR; Paolisso G; Barbieri M
Theranostics; 2023; 13(14):4872-4884. PubMed ID: 37771773
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor action in the vasculature.
Almutairi M; Al Batran R; Ussher JR
Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes.
Li J; Fu LZ; Liu L; Xie F; Dai RC
Med Sci Monit; 2017 Nov; 23():5410-5419. PubMed ID: 29133778
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway.
Ming-Yan Y; Jing Z; Shu-Qin G; Xiao-Liang B; Zhi-Hong L; Xue Z
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31383790
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
Haluzík M; Trachta P; Mráz M
Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
